Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Interferon alfa-2b
Drug ID BADD_D01167
Description Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Indications and Usage For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
Marketing Status approved
ATC Code L03AB05
DrugBank ID DB00105
KEGG ID D02745
MeSH ID D000077190
PubChem ID 71306834
TTD Drug ID D0P0WV
NDC Product Code 53713-0079; 0085-1168; 53713-0078; 53713-0081; 0085-4351; 0085-4352; 53713-0082; 53713-0080; 0085-1133; 0085-4350
UNII 43K1W2T1M6
Synonyms Interferon alpha-2 | Interferon alpha 2 | Interferon-alpha 2 | Interferon alpha-A | Interferon alpha A | LeIF A | IFN-alpha 2 | IFN-alpha-2 | Interferon alfa-2a | Interferon alfa 2a | Recombinant Interferon alpha-2a | Interferon alpha-2a, Recombinant | Recombinant Interferon alpha 2a | Roferon-A | Roferon A | RoferonA | Ro 22-8181 | Ro 22 8181 | Ro 228181 | Viferon | Sch-30500 | Sch 30500 | Sch30500 | Intron A (Interferon) | Reaferon | Interferon alfa-2b | Interferon alfa 2b | Interferon alpha-2b, Recombinant | Interferon alpha 2b, Recombinant | Recombinant Interferon alpha-2b | Recombinant Interferon alpha 2b | IFNalpha-2b, Recombinant | IFNalpha 2b, Recombinant | Recombinant IFNalpha-2b
Chemical Information
Molecular Formula C16H17Cl3I2N3NaO5S
CAS Registry Number 98530-12-2
SMILES CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphatic disorder01.09.01.003--Not Available
Nasal discomfort22.12.03.012--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Mucosal discolouration08.01.06.008--Not Available
Transaminases increased13.03.04.036--Not Available
Haemorrhage24.07.01.002--Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Bipolar disorder19.16.01.003--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Venous occlusion24.04.02.009--Not Available
Angiopathy24.03.02.007--Not Available
Neutropenic infection11.01.08.024; 01.02.03.009--Not Available
Urine output increased13.13.03.002--Not Available
Hot flush08.01.03.027; 24.03.01.005; 21.02.02.001--
Bacterial infection11.02.01.005--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Haemophilus infection11.02.15.001--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation08.01.05.007; 10.02.01.089--Not Available
Ischaemia24.04.02.004--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Spondylitis15.01.09.002--Not Available
Vaginal disorder21.08.01.005--Not Available
Cardiac valve disease02.07.02.001--Not Available
Abnormal behaviour19.01.01.001--Not Available
The 16th Page    First    Pre   16 17    Next   Last    Total 17 Pages